TARGET TO SPECIFIC LYMPHOID CELLS. PHASE I. MACROPHAGE TARGETING.

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$35,000.00
Award Year:
1983
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
763
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Vestar Research Inc.
939 East Walnut St., Pasadena, CA, 91106
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOSEPH A. ULIANA PH.D.
PRINCIPAL INVESTIGATOR
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
A THREE PHASE PROJECT IS PROPOSED TO COMMERCIALIZE FORMULATIONS OF PHOSPHOLIPID VESICLES CAPABLE OF DELIVERING IMMUNOGENIC SUBSTANCES TO SPECIFIC LYMPHOID CELLS. PHASE I IS A PROOF OF CONCEPT STUDY DESIGNED TO DEMONSTRATE THAT A VESICLE FORMULATION KNOWN TO AGGRESSIVELY TARGET TO MACROPHAGE IN VITRO CAN EVOKE STRONG MACROPHAGE MEDIATED IMMUNE RESPONSES TO OTHERWISE WEAK OR NONIMMUNOGENIC HAPTEN CONJUGATES IN VIVO. PHASE I EXPERIMENTS SPECIFICALLY ADDRESS THE MACROPHAGE MEDIATED B-CELL RESPONSE AND ARE DESIGNED TO DETERMINE THE SIGNIFICANCE OF THE SIZE OF THE HAPTEN CARRIER WHEN TARGETED WITH VESICLES. PHASE I SHOULD SUGGEST ANSWERS TO THE FOLLOWING QUESTIONS: 1) IS AN ENDOCYTOSED VESICLE PROCESSED AS AN IMMUNOGEN BEFORE OR AFTER LYSIS BY MACROPHAGE? 2) ARE LYSOZOME LABILE CARRIERS PROCESSED AS ANTIGENS OR DEGRADED WHEN ENDOCYTOSED WITHIN TARGETED VESICLES? 3) ARE HAPTEN-CONJUGATES, TARGETED TO MACROPHAGE BY VESICLE ENCAPSULATION, IMMUNOGENIC AT LOWER DOSAGES THAN CONVENTIONALLY INTRODUCED HAPTEN-CONJUGATES? SUCCESSFUL COMPLETION OF PHASE I WILL DEMONSTRATE THAT IMMUNE RESPONSE CAN BE ALTERED BY PRESENTING CHEMICAL SUBSTANCES TO SPECIFIC CELLS IN A MICROENCAPSULATED FORMULATION. PHASE II WILL EXTEND THIS PRELIMINARY INVES- TIGATION OF DELIVERING HAPTEN-CONJUGATE FORMULATIONS TO MACROPHAGE TO INCORPORATE HELPER T-CELL PARTICIPATION IN THEINITIAL ANTICIPATED T-CELL INDEPENDENT RESPONSE. THE PRODUCTION OF IMMUNE RESPONSES TO WEAKLY IMMUNOGENIC OR NON-IMMUNOGENIC MATERIALS HAS SIGNIFICANT SCIENTIFIC AND MEDICALAPPLICATIONS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government